Mariette Boerstoel | Senior Vice President, Worldwide Patient Safety Officer
Bristol Myers Squibb

Mariette Boerstoel-Streefland, MD, MBA, MSc(epi), has been in the pharmaceutical industry for 30 years, and is currently SVP, World Wide Patient Safety Officer at BMS. Mariette joined the pharmaceutical industry from clinical practice in 1989, and had a progressive career, holding various leadership positions in drug safety and medical affairs at Organon (now Merck), Mayne Pharma (now Hospira), Forest Labs (now Abbvie). In 2014 she joined Baxter/Baxalta to establish a new safety organization for the Bioscience division split of. With the Shire acquisition of Baxalta in 2016 she was appointed to integrate and lead the new safety organization. She joined Alexion as head of SVP Global Drug Safety in May 2018 to build out and strengthen the safety function. With the acquisition of Alexion by AZ she was appointed Chief Safety Officer, SVP Global patient safety to integrate, transform and lead the safety function for all therapeutic areas of AZ.
In August 2023 she joined BMS for a new challenge to be the SVP for Patient Safety. A common theme across the various roles has been organizational build or re-design, turn around management, change management, efficiency, and quality improvement initiatives. Mariette received her MD degree from the University of Utrecht, her master’s degree in Pharmaco-Epidemiology from McGill University Montreal and the University of Utrecht, and her MBA from New York Institute of Technology/Ellis College.